Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. is a U.S.-based pharmaceutical development company focused on repurposing approved drugs into patent-protected cancer therapies. Its current lead effort centers on itraconazole-based treatments for basal cell carcinoma nevus syndrome (BCCNS), with additional programs referenced for prostate and lung cancers.

3.19

3.19

— Inhibitor Therapeutics, Inc.
%
Lead oncology repurposing program55% Development of itraconazole-based therapies for BCCNS and related basal cell carcinoma indications.
Additional oncology indications20% Early-stage development work for prostate cancer and lung cancer using the same repurposing platform.
Formulation and delivery development15% Novel itraconazole formulation work intended to support pharmacokinetic studies and regulatory filings.
Intellectual property licensing10% Exclusive patent rights and know-how licensed from Johns Hopkins University and related IP assets.

The company does not sell commercial products today; its end customers are patients and physicians in oncology and...

  • BCCNS / basal cell carcinoma patientsprimary

    Patients targeted by the lead itraconazole program for BCCNS-related tumors and basal cell carcinoma.

  • Prostate and lung cancer patientssecondary

    Future patient populations for the company's patent-protected oncology expansion programs.

  • Regulatory agenciesprimary

    FDA reviewers and divisions that determine whether the company can advance to IND, trial, and NDA stages.

  • Clinical and formulation partnerssecondary

    External experts and Avior Bio supporting formulation, PK work, and regulatory preparation.

The company is headquartered in the United States and its development and regulatory work is centered there...

  • •Headquartered in the United States
  • •Clinical and FDA development work is U.S.-based
  • •Exclusive patent rights are worldwide
  • •No country-level revenue disclosure available
  • •Commercial exposure depends on U.S. regulatory progress

The core strategy is to repurpose an already approved active ingredient into patent-protected oncology therapies,...

01
Resolve FDA development path for BCCNSshort-term

Regulatory clarity determines whether the company needs more trials before NDA submission.

02
Complete novel itraconazole formulation workshort-term

The formulation supports PK comparison and may strengthen the regulatory package.

03
Expand the pipeline through licensing or acquisitionmedium-term

Additional assets could diversify risk beyond the lead BCCNS program.

The company is highly dependent on FDA review outcomes, timing, and interpretation of its development package, which...

high

FDA review and regulatory timing risk

The business depends on timely FDA feedback and approval of the development path.

Scope
Pre-IND, IND, and NDA submissions for BCCNS
Materiality
high
high

Need for additional clinical trials

If the FDA requires more data, development costs and timelines could increase materially.

Scope
HP2001 and future BCCNS studies
Materiality
high
high

Financing and dilution risk

The company may need to raise capital to fund development and future opportunities.

Scope
Public market capital raises
Materiality
high
medium

Program concentration risk

Value is concentrated in a small number of repurposed oncology programs.

Scope
BCCNS, prostate cancer, lung cancer
Materiality
high
medium

Regulatory shutdown / agency disruption risk

Government shutdowns can delay FDA and SEC processing and access to capital markets.

Scope
FDA and SEC review processes
Materiality
medium
Research and development expense recognition
Affects quarterly burn rate and comparability across periods
Intangible asset valuation and impairment
Could create non-cash charges if expected value declines
Management estimates and assumptions
Can affect accruals, provisions, and asset valuation
Future licensing and collaboration accounting
Could change reported revenue and deferred income balances

Inhibikase Therapeutics, Inc.

IKT · Biological Products, (No Diagnostic Substances)

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Inhibrx Biosciences, Inc.

INBX · Biological Products, (No Diagnostic Substances)

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

AIM ImmunoTech Inc.

AIM · Biological Products, (No Diagnostic Substances)

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

: 28.4.2026